Macrophage-1 antigen (or integrin αMβ2 or macrophage integrin or Mac-1) is a complement receptor ("CR3") consisting of CD11b (integrin αM) and CD18 (integrin β2).[1]
The integrin α chain is noncovalently bound to the integrin β chain. It binds to iC3b and can be involved in cellular adhesion, binding to the intercellular adhesion molecule-1 (ICAM-1).[2][3] CR3 causes phagocytosis and destruction of cells opsonized with iC3b. CR3 and CR4 are thought to exhibit overlapping functions; however, the distinct binding sites to iC3b suggests differences in their functions.[4] Additionally, CR3 has been shown to have therapeutic promise.[5][6][7]
Function
editMacrophage-1 antigen (hereafter complement receptor 3 or CR3) (CD11b/CD18) is a human cell surface receptor found on B and T lymphocytes, polymorphonuclear leukocytes (mostly neutrophils), NK cells, and mononuclear phagocytes like macrophages. CR3 is a pattern recognition receptor, capable of recognizing and binding to many molecules found on the surfaces of invading bacteria. CR3 also recognizes iC3b when bound to the surface of foreign cells. iC3b is generated by proteolysis of C3b and binding to the receptor causes phagocytosis and destruction of the foreign cell opsonized with iC3b.
CR3 belongs to a family of cell surface receptors known as integrins (because they share this particular β chain, they are referred to as β2-integrins), which are extremely widely distributed throughout nature and which generally are important in cellular adhesion, migration, phagocytosis and other cell-cell interactions in a variety of cells and circumstances.[4]
Upregulation of Mac-1 in the presence of certain factors such as IL-2 may cause a prolongation of the life of the immune cell while the presence of TNF-α induces apoptosis and selective removal of the cell.
A fully activated neutrophil may express on its membrane 200,000 or more CR3 molecules.
Absence of CR3 results in reduced binding and ingestion of Mycobacterium tuberculosis in mice. In human mononuclear phagocytes, phagocytosis of Mycobacterium tuberculosis is mediated in part by human monocyte complement receptors including CR3.[8]
CR3 has also been shown to mediate phagocytosis of the Lyme disease causing bacterium, Borrelia burgdorferi, in the absence of iC3b opsonization.[9]
CR3 and CR4
editCR3 (integrin αMβ2) and CR4 (integrin αXβ2, composed of CD11c and CD18), both members of the β2-integrin family, are generally thought to exhibit overlapping functions in myeloid cells and certain lymphoid populations.[4] CR3 and CR4 have been shown to be 87%[4] homologous via sequence analysis of human cDNA of the α chains; however, the complement receptors bind at distinct sites of iC3b and the intracellular domains differ in length and amino acid sequence, suggesting further differences in their functions.[4] Further, CR3 favors binding to positively charged species, while CR4 binds negatively charged species.[10] It has been shown that both CR3 and CR4 are found in mice and humans.[4] Together, CR3 and CR4 are involved in various functions of the T and B lymphocytes and NK cells. For instance, while both CR3 and CR4 are involved in adhesion, migration and proliferation of B cells, they are involved in enhancing complement-dependent cytotoxicity in NK cells.[4]
CR3 and CR4 for Disease Therapy
editImmunomodulatory therapies often aim for an induced reduction of symptoms in inflammatory disease or supported elimination of malignancies. In vitro and in vivo experiments suggest a response of CR3 and CR4 to enable complement-dependent cell cytotoxicity towards antibody-coated cancer cells.[5][6] Such biological therapeutic targeting is characterized by lowering autoimmune inflammation or enhancing anti-cancer vaccination effects.
Leukadherin-1, a CR3 agonist molecule, has been shown to suppress human innate inflammatory signals. Its anti-inflammatory effect mediation further provides support for its therapeutic promise in animal models of vascular injury.[7]
Synonyms and abbreviations
edit- CR3
- CD11b/CD18
- Macrophage 1 antigen (Mac-1)
See also
editReferences
edit- ^ Todd R (1996). "The continuing saga of complement receptor type 3 (CR3)". J. Clin. Invest. 98 (1): 1–2. doi:10.1172/JCI118752. PMC 507390. PMID 8690779.
- ^ Abbas AK, Lichtman AH, Pillai S (2017-03-10). Cellular and Molecular Immunology (Ninth ed.). Philadelphia, PA. ISBN 978-0-323-52323-3. OCLC 973917896.
{{cite book}}: CS1 maint: location missing publisher (link) - ^ Ross GD, Vĕtvicka V (May 1993). "CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions". Clinical and Experimental Immunology. 92 (2): 181–4. doi:10.1111/j.1365-2249.1993.tb03377.x. PMC 1554824. PMID 8485905.
- ^ a b c d e f g Erdei, Anna; Lukácsi, Szilvia; Mácsik-Valent, Bernadett; Nagy-Baló, Zsuzsa; Kurucz, István; Bajtay, Zsuzsa (2019). "Non-identical twins: Different faces of CR3 and CR4 in myeloid and lymphoid cells of mice and men" (PDF). Seminars in Cell & Developmental Biology. 85: 110–121. doi:10.1016/j.semcdb.2017.11.025. PMID 29174917. S2CID 6098102.
- ^ a b Hu, X.; Wohler, J. E.; Dugger, K. J.; Barnum, S. R. (2010-03-01). "2-Integrins in demyelinating disease: not adhering to the paradigm". Journal of Leukocyte Biology. 87 (3): 397–403. doi:10.1189/jlb.1009654. ISSN 0741-5400. PMC 3212424. PMID 20007244.
- ^ a b Joshi, Medha D.; Unger, Wendy J.; Storm, Gert; van Kooyk, Yvette; Mastrobattista, Enrico (2012). "Targeting tumor antigens to dendritic cells using particulate carriers". Journal of Controlled Release. 161 (1): 25–37. doi:10.1016/j.jconrel.2012.05.010. PMID 22580109.
- ^ a b Bednarczyk, Monika; Stege, Henner; Grabbe, Stephan; Bros, Matthias (2020-02-19). "β2 Integrins—Multi-Functional Leukocyte Receptors in Health and Disease". International Journal of Molecular Sciences. 21 (4): 1402. doi:10.3390/ijms21041402. ISSN 1422-0067. PMC 7073085. PMID 32092981.
- ^ Schlesinger LS, Bellinger-Kawahara CG, Payne NR, Horwitz MA (1990). "Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3". J. Immunol. 144 (7): 2771–80. doi:10.4049/jimmunol.144.7.2771. PMID 2108212. S2CID 7792492.
- ^ Hawley KL; Olson Jr. CM. (2012). "CD14 Cooperates with Complement Receptor 3 to mediate MyD88-Independent Phagocytosis of Borrelia burgdorferi". Proc Natl Acad Sci USA. 109 (4): 1222–32. Bibcode:2012PNAS..109.1228H. doi:10.1073/pnas.1112078109. PMC 3268315. PMID 22232682.
- ^ Vorup-Jensen, Thomas; Jensen, Rasmus Kjeldsen (2018-11-26). "Structural Immunology of Complement Receptors 3 and 4". Frontiers in Immunology. 9: 2716. doi:10.3389/fimmu.2018.02716. ISSN 1664-3224. PMC 6275225. PMID 30534123.
Further reading
edit- Wagner C, Hänsch GM, Stegmaier S, Denefleh B, Hug F, Schoels M (April 2001). "The complement receptor 3, CR3 (CD11b/CD18), on T lymphocytes: activation-dependent up-regulation and regulatory function". Eur. J. Immunol. 31 (4): 1173–80. doi:10.1002/1521-4141(200104)31:4<1173::AID-IMMU1173>3.0.CO;2-9. PMID 11298342. S2CID 44486940.
- Rooyakkers AW, Stokes RW (September 2005). "Absence of complement receptor 3 results in reduced binding and ingestion of Mycobacterium tuberculosis but has no significant effect on the induction of reactive oxygen and nitrogen intermediates or on the survival of the bacteria in resident and interferon-gamma activated macrophages". Microb. Pathog. 39 (3): 57–67. doi:10.1016/j.micpath.2005.05.001. hdl:2429/15708. PMID 16084683.
External links
edit- Macrophage-1+antigen at the U.S. National Library of Medicine Medical Subject Headings (MeSH)